Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409318 | 0.92 | MEN1 (0.41) | P2RX3MEN1KMT2ALMNAMAPT | |
| SCHEMBL2954311 | 0.89 | LMNA (0.48) | MEN1KMT2ATP53NPSR1LMNA | |
| SCHEMBL2337768 | 0.84 | TLR8 (0.37) | P2RX3TP53LMNAMAPTHTT | |
| SCHEMBL2945878 | 0.84 | TLR8 (0.41) | TP53LMNASMN1; SMN2MAPTPOLB | |
| SCHEMBL4408059 | 0.82 | P2RX3 (0.40) | P2RX3MEN1KMT2ATP53NPSR1 | |
| SCHEMBL4416624 | 0.82 | CNR2 (0.54) | P2RX3TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL662975 | 0.80 | LMNA (0.48) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL661098 | 0.79 | ALDH1A1 (0.36) | KMT2ATP53LMNAPOLBACSS2 | |
| SCHEMBL30361146 | 0.79 | ALDH1A1 (0.36) | KMT2ATP53LMNAPOLBACSS2 | |
| SCHEMBL661009 | 0.77 | ALDH1A1 (0.38) | MEN1KMT2ATP53NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | P2RX3 471/4885MEN1 1047/4885KMT2A 1901/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | P2RX3 471/4885MEN1 1047/4885KMT2A 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.